Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.57 |
| ▸ | F2 | P00734 | 3/20 | 0.57 |
| ▸ | C1S | P09871 | 1/20 | 0.57 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 3/20 | 0.52 |
| ▸ | F12 | P00748 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1436193 | 0.98 | PRSS1 (0.61) | PARP1PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL22573964 | 0.98 | PRSS1 (0.61) | PARP1PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL28551375 | 0.98 | PRSS1 (0.61) | PARP1PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL23540425 | 0.98 | PRSS1 (0.61) | PARP1PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL1435853 | 0.96 | PARP1 (0.59) | PARP1PRSS1PRSS2PRSS3F2 | |
| SCHEMBL15547311 | 0.83 | PRSS1 (0.70) | PRSS1PRSS2PRSS3F2C1S | |
| Hydrochloric Acid SCHEMBL28555629 | 0.80 | PRSS1 (0.74) | PRSS1PRSS2PRSS3F2C1S | |
| Hydrochloric Acid SCHEMBL28253026 | 0.80 | PRSS1 (0.74) | PRSS1PRSS2PRSS3F2C1S | |
| SCHEMBL284142 | 0.77 | PARP1 (1.00) | PARP1CES2CES1PKMBLM | |
| SCHEMBL2031034 | 0.77 | PARP1 (0.63) | PARP1CES2CES1PKMCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118507836-B | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118507836-A | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| CN-118507836-B | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118507836-A | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20240150506-A1 | CURING AGENTS FOR FLUOROELASTOMERS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| CN-117529520-A | Fluoroelastomer compositions containing curative | 杜邦特种产品美国有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4305096-A1 | FLUOROELASTOMERS COMPOSITION COMPRISING CURING AGENTS | Dupont Specialty Products USA, LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192006-A1 | FLUOROELASTOMERS COMPOSITION COMPRISING CURING AGENTS | DUPONT POLYMERS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-109153649-B | Allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3433234-B1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004062609-A2 | PYRIMIDINE DERIVATIVES AS IL-8 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | PHARMACOPEIA, LLC | 2004-05-06 | — | — | US | disclosed |
| CN-1134264-C | antithrombotic agent | — | 2004-01-14 | — | — | CN | disclosed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
| CN-1147205-A | antithrombotic agent | LILLY CO ELI (US) | 1997-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, G6PC1 | PARP1 923/4885PRSS1 283/4885PRSS2 1024/4885 |
| US-20040087601-A1 | Pyrimidine derivatives as IL-8 receptor antagonists | CXCL8, IL1RN, IL18 | PARP1 2763/4885PRSS1 3442/4885PRSS2 4101/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | PARP1 3023/4885PRSS1 2532/4885PRSS2 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.